Sandoz Maintains Lead On Denosumab With First EU Recommendations
CHMP Positive Opinions Follow Soon After First USFDA Approvals
Sandoz has again demonstrated its clout in the biosimilars space, taking a major step towards obtaining pan-European marketing authorizations for its biosimilar Prolia/Xgeva products.
